MELT - MRI Evaluation of Lymphoma Treatment

Study Overview
=================
Brief Summary
-----------------
Patients who are newly diagnosed with Hodgkin's lymphoma will undergo disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo an extended MRI scan.

Detailed Description
-----------------
The trial will be a single centre cohort study in patients newly diagnosed with Hodgkin's lymphoma undergoing disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo advanced anatomical and functional MRI sequences.

Official Title
-----------------
Whole Body Functional and Anatomical MRI: Accuracy in Staging and Treatment Response Monitoring in Adolescent Hodgkin's Lymphoma Compared to Conventional Multimodality Imaging

Conditions
-----------------
Lymphoma, Hodgkin

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 5 to 20 years (inclusive) with participant and parent/guardian informed consent Histologically confirmed first presentation of Hodgkin's Lymphoma Either entered into the Euronet PHL-C1 trial or LP1 trials OR not formally entered into the Euronet trials but treated on the chemotherapy regimens of the Euronet trials for classical and lymphocyte predominant Hodgkin Lymphoma Exclusion Criteria: Contraindications to MRI (e.g. pacemaker) Previous malignancy or previous chemotherapy or radiotherapy treatment for malignancy Pregnancy or nursing

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The per site sensitivity and specificity of MRI for both nodal and extranodal sites and concordance in final disease stage with the multi-modality reference standard |  | The recruited patients to be followed up for 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of correct patient classifications into therapy responders and non-responders by MRI compared to the multi modality reference |  | The recruited patients to be followed up for 1 year | 
| Inter observer agreement for MRI between reporting radiologists (on site and off site). responders by MRI compared to the multi modality reference |  | The recruited patients to be followed up for 1 year | 
| Sensitivity, specificity of qualitative assessment of Minimum intensity projection (MIP) inverted high B value datasets |  | The recruited patients to be followed up for 1 year | 
| Utility of apparent diffusion coefficient (ADC) histogram analysis for identifying responsive nodal disease |  | The recruited patients to be followed up for 1 year | 
| Simulated effect of MRI on clinical management via external oncologic review |  | The recruited patients to be followed up for 1 year |